Daclizumab

What is Daclizumab?

Daclizumab is a humanized monoclonal antibody designed to act as an immunosuppressant. Developed to target the alpha subunit (CD25) of the interleukin-2 receptor (IL-2R), it was historically used in the treatment of relapsing-remitting multiple sclerosis (RRMS) under the brand name Zinbryta, and also for the prevention of acute organ transplant rejection. Its unique mechanism of action aimed to modulate the immune system by specifically inhibiting certain immune cell activities.

While Daclizumab represented a significant advancement in therapeutic options for its time, especially in neurology, its use has been re-evaluated due to safety concerns. Understanding its properties, mechanism, and historical applications remains crucial for those studying immunology and pharmacology.

How Does it Work?

The primary mechanism of action for Daclizumab revolves around its interaction with the interleukin-2 receptor (IL-2R). Interleukin-2 (IL-2) is a cytokine crucial for the proliferation and differentiation of T-lymphocytes, which are key players in immune responses and inflammation. The IL-2R exists in various forms, but Daclizumab specifically targets the CD25 subunit, also known as the alpha chain, which is highly expressed on activated T-cells.

By binding to CD25, Daclizumab prevents IL-2 from attaching to its receptor. This blockade effectively inhibits the signaling pathway initiated by IL-2, leading to a reduction in T-cell activation and proliferation. The net effect is a selective immunosuppressive action, particularly impacting activated T-cells that drive autoimmune processes or transplant rejection. This targeted approach was intended to provide immune modulation with fewer widespread side effects compared to non-selective immunosuppressants.

Medical Uses

Daclizumab has been utilized in two primary medical areas:

• Relapsing-Remitting Multiple Sclerosis (RRMS)

  For a period, Daclizumab (Zinbryta) was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in adults. It was shown to reduce the frequency of relapses and slow the progression of disability in patients. Its once-monthly subcutaneous administration offered a convenient dosing schedule for many patients. However, due to serious safety concerns, including severe liver injury and inflammatory brain disorders, its marketing authorization for MS was voluntarily withdrawn globally in 2018.

• Prevention of Acute Organ Transplant Rejection

  Historically, Daclizumab was also used for the prophylaxis of acute organ transplant rejection, particularly in renal transplant recipients. Administered intravenously, it helped to reduce the incidence of acute rejection episodes by mitigating the immune response against the transplanted organ. While its use in transplantation has largely been superseded by newer agents, it played a significant role in early immunosuppressive regimens.

Dosage

The dosage of Daclizumab varied depending on its intended use:

• For Relapsing-Remitting Multiple Sclerosis: When it was available for RRMS, the typical dose was 150 mg administered by subcutaneous injection once monthly. It was often initiated under the supervision of a physician experienced in treating MS.
• For Organ Transplant Rejection: In the context of transplant rejection prophylaxis, Daclizumab was typically administered intravenously. The exact dosing regimen could vary but often involved several doses around the time of transplantation.

It is crucial to remember that Daclizumab is no longer widely available for either indication, particularly for MS. Any decision regarding its use or similar therapies must be made by a qualified healthcare professional, considering the patient's individual circumstances and the latest medical guidelines.

Side Effects

While Daclizumab offered therapeutic benefits, it was associated with several side effects, some of which were severe and led to its withdrawal from the MS market:

• Common Side Effects

  • Headache
  • Rash, dermatitis, or eczema
  • Nasopharyngitis
  • Elevated liver enzymes (transaminases)
  • Infections (e.g., upper respiratory tract infections)
  • Depression or anxiety

• Serious Side Effects

  The most concerning side effects included:

  • Severe Liver Injury: Cases of severe liver injury, including liver failure requiring transplant and some fatalities, were reported. This necessitated regular liver function monitoring for patients on Daclizumab.
  • Inflammatory Brain Disorders: Serious inflammatory brain disorders, some resembling autoimmune encephalitis, occurred in some patients. These could lead to neurological impairment.
  • Serious Infections: Increased risk of serious infections, including opportunistic infections, due to its immunosuppressive effects.
  • Depression and Suicidal Ideation: There were reports of severe depression, mood changes, and suicidal ideation, prompting close psychiatric monitoring.
  • Other Autoimmune Conditions: Rare cases of other autoimmune conditions, such as autoimmune colitis, were observed.

Drug Interactions

Due to its immunosuppressive nature and potential for serious adverse effects, Daclizumab could have significant drug interactions:

• Other Immunosuppressants: Concomitant use with other immunosuppressive agents could increase the risk of severe infections, malignancy, and profound immune suppression.
• Hepatotoxic Drugs: Given the risk of severe liver injury associated with Daclizumab, caution was advised when co-administering it with other drugs known to cause liver toxicity. Close monitoring of liver function would be essential.
• Live Vaccines: As with other immunosuppressants, live vaccines were generally contraindicated during Daclizumab treatment due to the risk of vaccine-induced infection.

Patients should always inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential interactions.

FAQ

• Is Daclizumab still available for use?

  Daclizumab, particularly under the brand name Zinbryta for MS, was voluntarily withdrawn from the market globally in 2018 due to safety concerns. Its use in transplant settings has also largely diminished in favor of newer agents.

• What was Daclizumab primarily used for?

  Historically, Daclizumab was used for the treatment of relapsing-remitting multiple sclerosis (RRMS) and for the prevention of acute organ transplant rejection.

• How was Daclizumab administered?

  For MS, it was administered as a once-monthly subcutaneous injection. For transplant rejection prophylaxis, it was typically given via intravenous infusion.

• What were the most serious side effects of Daclizumab?

  The most serious side effects included severe liver injury (including liver failure), inflammatory brain disorders, serious infections, and psychiatric events like severe depression and suicidal ideation.

• Why was Daclizumab withdrawn from the market?

  It was withdrawn due to the occurrence of serious and unpredictable side effects, particularly severe liver injury and inflammatory brain disorders, which outweighed its clinical benefits for MS patients.

Products containing Daclizumab are available through trusted online pharmacies. You can browse Daclizumab-based medications at ShipperVIP or Medicenter.

Summary

Daclizumab is a humanized monoclonal antibody that functioned as a selective immunosuppressant by targeting the CD25 subunit of the interleukin-2 receptor. It held a significant, albeit brief, role in the treatment of relapsing-remitting multiple sclerosis (RRMS) and in preventing acute organ transplant rejection. While it demonstrated efficacy in these areas, its use for MS was voluntarily withdrawn globally in 2018 due to serious safety concerns, including severe liver injury and inflammatory brain disorders. This underscores the critical importance of continuous pharmacovigilance and risk-benefit assessment in pharmaceutical development and patient care. Although its clinical availability is now limited, Daclizumab remains an important case study in the evolving landscape of targeted immunotherapies.